WO1999042578A3 - Modulation of cell proliferation, methods and reagents - Google Patents

Modulation of cell proliferation, methods and reagents Download PDF

Info

Publication number
WO1999042578A3
WO1999042578A3 PCT/US1999/002115 US9902115W WO9942578A3 WO 1999042578 A3 WO1999042578 A3 WO 1999042578A3 US 9902115 W US9902115 W US 9902115W WO 9942578 A3 WO9942578 A3 WO 9942578A3
Authority
WO
WIPO (PCT)
Prior art keywords
reagents
modulation
methods
cell proliferation
polypeptides
Prior art date
Application number
PCT/US1999/002115
Other languages
French (fr)
Other versions
WO1999042578A2 (en
Inventor
James Hudson
Gregory J Hannon
David H Beach
Original Assignee
Cold Spring Harbor Lab
James Hudson
Gregory J Hannon
David H Beach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab, James Hudson, Gregory J Hannon, David H Beach filed Critical Cold Spring Harbor Lab
Priority to EP99904505A priority Critical patent/EP1051490A2/en
Priority to AU24890/99A priority patent/AU760252B2/en
Priority to JP2000532518A priority patent/JP2003518359A/en
Priority to IL13719799A priority patent/IL137197A0/en
Priority to CA002318811A priority patent/CA2318811A1/en
Publication of WO1999042578A2 publication Critical patent/WO1999042578A2/en
Publication of WO1999042578A3 publication Critical patent/WO1999042578A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to polypeptides capable of bypassing a cell cycle checkpoint. Specific applications for inducing cell growth using such polypeptides (e.g., a macrophage migration inhibitory factor) are described.
PCT/US1999/002115 1998-01-30 1999-01-29 Modulation of cell proliferation, methods and reagents WO1999042578A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99904505A EP1051490A2 (en) 1998-01-30 1999-01-29 Modulation of cell proliferation, methods and reagents
AU24890/99A AU760252B2 (en) 1998-01-30 1999-01-29 Modulation of cell proliferation, methods and reagents
JP2000532518A JP2003518359A (en) 1998-01-30 1999-01-29 Regulation of cell proliferation, methods and reagents
IL13719799A IL137197A0 (en) 1998-01-30 1999-01-29 Modulation of cell proliferation, methods and reagents
CA002318811A CA2318811A1 (en) 1998-01-30 1999-01-29 Modulation of cell proliferation, methods and reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7325798P 1998-01-30 1998-01-30
US60/073,257 1998-01-30

Publications (2)

Publication Number Publication Date
WO1999042578A2 WO1999042578A2 (en) 1999-08-26
WO1999042578A3 true WO1999042578A3 (en) 1999-12-23

Family

ID=22112690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/002115 WO1999042578A2 (en) 1998-01-30 1999-01-29 Modulation of cell proliferation, methods and reagents

Country Status (6)

Country Link
EP (1) EP1051490A2 (en)
JP (1) JP2003518359A (en)
AU (1) AU760252B2 (en)
CA (1) CA2318811A1 (en)
IL (1) IL137197A0 (en)
WO (1) WO1999042578A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133552A2 (en) * 1998-11-25 2001-09-19 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
DE19964287B4 (en) * 1999-11-26 2007-05-16 Fraunhofer Ges Forschung Screening drugs disrupting macrophage migration inhibitory factor-cJun activation domain binding protein1 interaction involves comparing MIF-Jab1 interaction, in presence and absence of drug in MIF and Jab1 system
DE19957065B4 (en) 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening procedure for drugs
DK1485090T3 (en) * 2002-03-08 2008-02-04 Novartis Ag Combinations comprising an epothilone derivative and an imidazotetrazinone
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
LT3494960T (en) * 2008-03-27 2021-02-25 Helsinn Healthcare Sa Stabilized compositions of alkylating agents and methods of using same
CN105132395A (en) * 2009-03-09 2015-12-09 生物蛋白有限公司 Mirac proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015242A2 (en) * 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
WO1997041433A1 (en) * 1996-04-29 1997-11-06 Cancer Research Campaign Technology Limited METHOD AND MEANS FOR DISRUPTION OF p53 AND RB INTERACTION
WO1998007886A1 (en) * 1996-08-19 1998-02-26 Ventana Genetics, Inc. Process for identification of genes encoding proteins having cell proliferation-promoting activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015242A2 (en) * 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
WO1997041433A1 (en) * 1996-04-29 1997-11-06 Cancer Research Campaign Technology Limited METHOD AND MEANS FOR DISRUPTION OF p53 AND RB INTERACTION
WO1998007886A1 (en) * 1996-08-19 1998-02-26 Ventana Genetics, Inc. Process for identification of genes encoding proteins having cell proliferation-promoting activity

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AGARWAL M.L. ET AL.: "p53 controls both the G2/M and the G1 cell cycle checkoints and mediates reversible growth arrest in human fibroblasts", PROC. NATL. ACAD. SCI. USA, vol. 92, August 1995 (1995-08-01), pages 8493 - 8497, XP002108341 *
BOND J A ET AL: "ESCAPE FROM SENESCENCE IN HUMAN DIPLOID FIBROBLASTS INDUCED DIRECTLY BY MUTANT P53", ONCOGENE, vol. 9, no. 7, 1 July 1994 (1994-07-01), pages 1885 - 1889, XP000614396, ISSN: 0950-9232 *
CHEN C.Y. ET AL.: "Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.", PROC. NATL. ACAD. SCI. USA, vol. 91, March 1994 (1994-03-01), pages 2684 - 2688, XP002108338 *
DIJKE TEN P ET AL: "GROWTH FACTORS FOR WOUND HEALING", BIO/TECHNOLOGY, vol. 7, no. 8, 1 August 1989 (1989-08-01), pages 793 - 798, XP000073312, ISSN: 0733-222X *
DULIC V. ET AL.: "p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.", CELL, vol. 76, 25 March 1994 (1994-03-25), pages 1013 - 1023, XP002116810 *
KAGAWA S. ET AL.: "p53 expression overcomes p21WAF/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells.", ONCOGENE, vol. 15, no. 16, 16 October 1997 (1997-10-16), pages 1903 - 1909, XP002108723 *
KOUZARIDES T: "FUNCTIONS OF PRB AND P53: WHAT'S THE CONNECTION?", TRENDS IN CELL BIOLOGY, vol. 5, no. 12, 1 December 1995 (1995-12-01), pages 448 - 450, XP002039967, ISSN: 0962-8924 *
KUBBUTAT M.H.G. ET AL.: "Regulation of p53 stability by Mdm2", NATURE, vol. 387, May 1997 (1997-05-01), pages 299 - 303, XP002108339 *
NOZAKI T. ET AL.: "Abrogation of G1 arrest after DNA damage is associated with constitutive overexpression of Mdm2, Cdk4, and Irf1 mRNAs in the BALB/c 3T3 variant 1-1 clone.", BIOCHEM. BIOPHYS. RES. COMM., vol. 233, 1997, pages 216 - 220, XP002108340 *
PARALKAR V ET AL: "MIF: AN ESSENTIAL INTERMEDIATE FOR GROWTH FACTOR INDUCED MITOGENESIS", FASEB J., vol. 9, no. 6, 1995, pages A1332, XP002002563 *
SHIMIZU T. ET AL.: "Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization", FEBS LETT., vol. 381, 1996, pages 199 - 202, XP002116811 *
SHIMIZU T. ET AL.: "Macrophage Migration Inhibitory Factor is an essential immunoregulatory cytokine in atopic dermatitis", BIOCHEM. BIOPHYS. RES. COM., vol. 240, 1997, pages 173 - 178, XP002116812 *

Also Published As

Publication number Publication date
IL137197A0 (en) 2001-07-24
WO1999042578A2 (en) 1999-08-26
JP2003518359A (en) 2003-06-10
AU760252B2 (en) 2003-05-08
CA2318811A1 (en) 1999-08-26
EP1051490A2 (en) 2000-11-15
AU2489099A (en) 1999-09-06

Similar Documents

Publication Publication Date Title
AU5435798A (en) Thin, planar heat spreader
ZA98417B (en) Gas phase polymerization process.
DE59104146D1 (en) Primer for metallizing substrate surfaces.
WO1999042578A3 (en) Modulation of cell proliferation, methods and reagents
WO2000015798A3 (en) Mammalian transforming growth factor beta - 9 (ztgfss9)
AU8016894A (en) Betaglycan polypeptides having tgf-beta binding activity
AU2485997A (en) Method for modified aminoplast compounds, aminoplast compounds obtained thereby and coatings containing the same
AU8620698A (en) Antifreeze proteins, dna and expression systems
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
AU739516C (en) Novel lantibiotic related to actagardine, and processes for the preparation and use thereof
NO168762C (en) COATED, FLAT GLASS.
AU1110297A (en) Novel dnas, novel polypeptides and novel antibodies
AU7638498A (en) Cyanoguanidines as cell proliferation inhibitors
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU5696796A (en) Recombinant preduodenal lipases and polypeptides derivatives produced by plants, processes for obtaining them and their uses
GB9710762D0 (en) Binding complexes
AU2590201A (en) Trefoil domain-containing polynucleotides, polypeptides, and antibodies
AU1137699A (en) Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor
AU2389200A (en) Cell cycle nucleic acids, polypeptides and uses thereof
AU5800996A (en) Nes-1 polypeptides, dna, and related molecules and methods
AU2808392A (en) C-myc dna binding partners, motifs, screening assays, and uses thereof
AU5491599A (en) Irak3 polypeptides, polynucleotides and methods
AU2161699A (en) Peptides and nucleic acids derived from (eisenia foetida) and the use thereof
AU1571299A (en) Polypeptides, polynucleotides and uses thereof
AU5563699A (en) Analogs of udp-murnac peptides, assays and kits

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 137197

Country of ref document: IL

Ref document number: 24890/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999904505

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2318811

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2318811

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09628220

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 532518

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999904505

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 24890/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999904505

Country of ref document: EP